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 ABSTRACT 
 
 
 The aim of the work is to develop Bi-layered matrix tablets containing a 
Biguanide (API I) in SR layer and a Thiazolidinedione (API II) in IR layer. The 
formula is developed by taking In-vitro release of both the drugs in to consideration. 
HPMC K 4M, HPMC K 15M and HPMC K 100M were used as rate retarding 
polymers and Croscarmellose sodium as superdisintegrant for SR layer and IR layer 
respectively,  in the trials for preparing an optimum formulation of the Bi-Layer 
tablets. Pre-formulation studies and Compatibility studies were found to be 
satisfactory. Tablet blend all formulations was evaluated for flow properties, which 
were found to be optimum. Tablet prepared were evaluated for several parameters like 
Thickness, Hardness, Weight variation, Friability, Drug content and In-vitro release of 
the drugs. Formulation F-7 was found to be an optimum formula with the release of 
the API I and API II within specifications. The release rate was found to be following 
First-order kinetics and mechanism is by combination of diffusion and erosion. 
Stability studies at conditions 30°C/ 65%RH and 40°C/75%RH are showing that the 
dosage form is intact after storage for 3 months at both the conditions. It can be 
concluded that Bi-layered tablets of these drugs are advantageous in having uniform 
drug content of both the drugs and the sustained release of the API I reduces the 
dosing frequency thereby improving patient compliance. 
  
1. INTRODUCTION 
Definition1: 
Tablets are solid preparations each containing a single dose of one or more 
active substances and usually obtained by compressing uniform volumes of particles. 
Tablets are intended for oral administration. Some are swallowed whole, some after 
being chewed, some are dissolved or dispersed in water before being administered and 
some are retained in the mouth where the active substance is liberated. 
The particles consist of one or more active substances with or without 
excipients such as diluents, binders, disintegrating agents, glidants, lubricants, 
substances capable of modifying the behaviour of the preparation in the digestive 
tract, colouring matter authorized by the competent authority and flavouring 
substances. 
 Classification of Tablets2: 
 Most commercial tablets are divided into two general classes, by whether they 
are made by compression or molding. Compressed tablets are prepared by large scale 
production methods, while molded tablets generally involve in small scale production. 
Various tablet types are listed below. 
¾ Compressed tablets 
¾ Molded tablets. 
Compressed tablets are of again of following types: 
• Sugar coated tablets. 
• Film-coated tablets. 
• Enteric coated tablets 
• Multiple compressed tablets 
• Controlled release tablets 
• Tablets for solution 
• Effervescent tablets 
• Compressed Suppositories or inserts 
• Buccal or sublingual tablets. 
Molded tablets are also called as Tablet Triturates can be of two types. These are 
manufactured in small scale. Two types of Molded tablets are given below. 
• Dispensing tablets 
• Hypodermic tablets 
Advantages of Tablets3: 
 Of all the oral solid dosage forms tablets are most commonly employed, tablet 
has several advantages: 
9 They are unit dosage forms, so they offer the greatest capabilities of all oral 
dosage forms for the greatest dose precision and least content variability. 
9 Their cost is lowest of all dosage forms. 
9 They are lightest and most compact of all oral dosage forms. 
9 They are in general easiest and cheapest to package and ship of all oral dosage 
forms. 
9 Product identification is potentially the simplest and cheapest requiring no 
additional processing steps when employing an embossed or monogramming 
punch face. 
9 They lend themselves to certain special release profiles products, such as 
enteric or delayed release products. 
9 They are better suited to large scale production than other unit oral dosage 
forms. 
9 They have best combined properties of chemical, mechanical and 
microbiological stability of all dosage forms. 
Disadvantages of Tablets3: 
9 Some of the drugs resist compression into dense compacts, owing to their 
amorphous nature or flocculent, low-density character. 
9 Drugs with poor wetting, slow dissolution properties, intermediate to large 
dosages, or any combination of these features may be difficult or impossible to 
formulate and manufacture as a tablet that still provide adequate or full drug 
availability. 
9 Tablets cannot be suggested for the patients with Dysphagia (difficulty in 
swallowing). 
Multiple compressed tablets1: 
 These are compressed tablets made by more than one compression cycle.  This 
process is best used when there is need of separating active ingredients for stability 
purposes or if mixing is inadequate to guarantee uniform distribution of two or more 
active ingredients. 
 They are of two types again 
• Layered tablets 
• Press coated tablets. 
  
Layered tablets: Layered tablets are formed by compressing the granules on 
previously compressed blend (First layer). This forms two layers and can be used for 
making tablets of multilayer. This requires Special Presses, when it comes to large 
scale manufacturing. 
 
Press coated tablets: Press coated tablets are formed by compressing the granules 
having already compressed tablets in the core. This forms a dry coat over the core 
tablets. Special presses are developed for the large scale processes recently.  
                          
                                                                                    Core              Coating 
  
Layered tablets: 
Bi-layered tablet are mostly explored by the pharmaceutical companies not 
just for the sake of extension of the patents and marketing of the drugs, but also for 
sake of Bi-modular release of the drugs and to incorporate two drugs in one tablet. 
There are many formulations of tablets comprising two drug molecules, but there is 
always possibility of interaction. Bi-layer tabletting is a better option of avoiding the 
interaction between two different classes of molecules. 
Bi-layer tablets are having an advantage of accommodating the layers of two 
different kinetic profiles of a drug, of which one can be an immediate release layer 
and other a prolonged release layer (Chan,   et al.,)4. There are some works that have 
two drug molecules in different layers, one drug layer immediately releases and other 
drug layer is designed to release in delayed or extended time. (Vaya, et al)5.  
               Preparing the bi-layered tablets is feasible with all desired parameters at 
small scale. But when transforming the process to a large scale process, the 
parameters desired are difficult and nearly impossible to obtain. To obtain desired bi-
layered tablets, special presses are obviously required to avoid the risks like 
9 Improper weights of the individual layers. 
9 Separation of the layers. 
9 Cross-contamination of layers. 
9 Hardness problems. 
Layered tablet press6: 
 In the earlier times the machines fed controlled volumes of each separate 
granulation on top of each other and compressed them together at one pressing station. 
The machines of later stages were engineered to compress each layer separately 
before deposition of next granulation, with a final compression for the complete 
tablet.  
Wipe-off blades covering the entire face of the die have been installed not to 
allow the excess blend to circulate around the turret. The excess is directed in to pots 
at the side of the press and manually returned to the appropriate hopper. Suction 
pumps were used to remove any blend that escaped the scraper blades.  
 The latest refinement is has been the force feeders which retain the individual 
granulations. But some powder escapes from these also, and same arrangement as 
described is installed on the presses to prevent one granulation from contaminating the 
other. 
 In the operation of older type of machine, the granulation for the first layer is 
placed in the hopper, and the machine is adjusted until the desired weight is achieved 
with consistency; then the second hopper is filled with the granulation, and the same 
procedure is followed until the correct tablet weight is obtained. In this, the single-
compression method, the delineation between the layers tends to be little uneven. It is 
also difficult to adjust the weight during the run. 
Of the modern machines, there are two types which differ mainly in the way 
the layers are separated for weight and hardness checking. In one, the first layer is 
diverted from the machine. In the other, the first layer is made so hard that the second 
layer will not bond to it or will bond only weekly; upon ejection of complete tablet, 
the layers are separated and tested individually.  
 • A granulation is placed in the in the first hopper that flows in to the feed frame. The 
machine is started and the volume of granulation in the die is adjusted by the weight 
adjustment cam. 
• The upper and lower punches are brought together by the pre-compression rolls. To 
form a weak compact. Part of lower cam track is raised hydraulically to eject the first 
layer, which is swept off the die table by the wipe-off blades affixed to the back edge 
of the second feeder. 
• Samples are weighed and hardness is determined, when conditions are satisfactory, 
the ejection cam is lowered and the entire process is repeated for the second layer, 
using feed frame,  weight adjusting cam tamping rolls and ejection cam and wipe-off 
blades.  
•   The weight of second layer is determined by the difference between the two weights. 
• The leading and trailing edges of the feed frames are equipped with wipe-off blades 
which divert any powders that escape from the feeders in to the collection boxes. The 
blade of the trailing edge of first feed frame guides the completed tablet down the 
chute to the collection bin. 
• If an adjustment in the weight or thickness of the first or second layer is necessary, 
then weight of each succeeding layer will probably need correction as weight is 
related to fill volume 
 Diabetic Mellitus7: 
Diabetes mellitus is a heterogeneous group of disorders characterized by 
abnormalities in carbohydrate, protein, and lipid metabolism. The central disturbance 
in diabetes mellitus is an abnormality in insulin production or action or both, although 
other factors can be involved. Hyperglycemia is a common end point for all types of 
diabetes mellitus and is the parameter that is measured to evaluate and manage the 
efficacy of diabetes therapy. 
 
Diabetes mellitus has been traditionally classified into Insulin-dependent 
diabetes mellitus (IDDM), also known as type I (formerly called juvenile-onset 
diabetes mellitus), and non–insulin-dependent diabetes mellitus (NIDDM), also 
known as type II.  
 
Type I Diabetes mellitus constitutes about 10% of cases of diabetes mellitus. 
The pathogenesis of type I diabetes is autoimmune destruction of the cells of the 
Figure 1: Double sided rotary press that can be tooled 
for Bi-layered compression of tablets; Oystar by 
Manesty. 
pancreas. The factor or factors that trigger this autoimmune response are unknown. 
Predisposing factors appear to include certain major histocompatibility complex 
haplotypes and auto-antibodies to various islet cell antigens. The progression of the 
autoimmune response is characterized by lymphocytic infiltration and destruction of 
the pancreatic cells resulting in insulin deficiency. 
 
 Type II Diabetes mellitus, is far more common. In contrast to Type I, Type II 
is not an autoimmune process and may or may not be insulin dependent; that is, a 
diabetic state that is most effectively managed by insulin therapy. Frequently, NIDDM 
is used interchangeably with type II diabetes mellitus. The three major metabolic 
abnormalities that contribute to hyperglycemia in NIDDM are defective glucose-
induced insulin secretion, increased hepatic glucose output, and inability of insulin to 
stimulate glucose uptake in peripheral target tissues. 
 
There are several complications that arise due to Diabetes such as Diabetic 
Keto-acidosis, Macro-vascular diseases, Micro-angiopathy, dysfunction of vascular 
endothelium. There is a risk of formation of oxygen derived free radicals. Chronic 
renal failure is another complication where Diabetes becomes a reason.  
Management of Diabetes Mellitus: 
 WHO provides guidelines for the management of Diabetes Mellitus. It was 
suggested that the major components8 of treatment of Diabetes are  
• Diet with exercise 
• Oral-Hypoglycemic drugs. 
• Insulin. 
Type 2 diabetes is a syndrome characterized by insulin deficiency, insulin 
resistance and increased hepatic glucose output. Medications used to treat Type 2 
Diabetes are designed to correct one or more of these metabolic abnormalities7. 
Currently, there are five distinct classes of hypoglycemic agents available, each class 
displaying unique pharmacologic properties. There are five important classes of Oral 
Hypoglycemic drugs namely, 
• Sulfonylureas 
• Biguanides 
• Meglitinides 
• Thiazolidinediones 
• Alpha-Glucosidase inhibitors. 
 
 
TABLE 1 Showing various classes of Oral-Hypoglycemic drugs. 
 
  
       Sulfonylureas 
 
Biguanides 
 
Meglitinides 
 
Thiazolidinediones 
 
α-Glucosidase 
inhibitors 
First generation: 
Tolbutamide,                      
Acetohexamide,  
Chlorpropamide 
 
Metformin  Repaglinide, 
Nateglinide 
Pioglitazone, 
Rosiglitazone 
Acarbose, 
Voglibose, 
Miglitol 
Second generation:  
Glimipride,  
Glyburide, Gliclazide 
Combination of Oral-Hypoglycemic Drugs9: 
  If adequate control is not obtained with the use of a single agent, combination 
therapy is an option. Several of the available oral agents have been studied in combination 
and have been shown to further improve glucose control when compared to monotherapy. As 
with monotherapy, the choice of a second agent should be based on individual characteristics. 
Reasonable combinations of agents include the following, 
 Sulfonylurea+ Biguanide or Thiazolidinedione or Alpha Glucosidase 
inhibitors. 
 Biguanide+ Meglitinide 
 Biguanide + Thiazolididnedione 
 Biguanide + Alpha- glucosidase inhibitors. 
       
Triple combination is therapy is done with: 
 Sulfonylurea + Biguanide + Thiazolidinedione. 
 Sulfonylurea + Biguanide + Alpha-Glucosidase inhibitors. 
 
Biguanides7 does not affect insulin secretion but requires the presence of 
insulin to be effective. The exact mechanism of Biguanide’s action is not clear, but it 
does decrease hepatic glucose production and increase peripheral glucose uptake. 
When used as monotherapy, Biguanides rarely causes hypoglycemia. 
 
Thiazolidinediones7 (sometimes termed glitazones) are a novel class of drugs 
that were initially identified for their insulin-sensitizing properties. They all act to 
decrease insulin resistance and enhance insulin action in target tissues. 
Thiazolidinediones activate the nuclear peroxisome proliferator–activated receptor 
(PPAR), a nuclear orphan receptor that is predominantly expressed in adipose tissue 
and to a lesser extent in muscle, liver, and other tissues. 
 
Biguanides act by inhibiting the hepatic glucose output and to a lesser extent 
by enhancing the Insulin sensitivity in hepatic and some peripheral tissues. The 
glucose level in the body is found to be reduced up to 50 to 70 mg/dL. 
Thiazolidinediones act by increasing the sensitivity in the Adipose tissues and 
muscles and to a lesser extent by reducing the hepatic output of glucose. 
 These are found to be reducing the hepatic glucose by 25 to 50 mg/dL. So it 
can be implied that combination of these two classes can have Synergistic effect over 
glucose regulation.  
SUSTAINED RELEASE FORMULATIONS: 
During a course of therapy, patient is advised to take medicines more than 
once a day. This can be because of fast elimination of the drug from the body. To 
maintain the drug concentration within the therapeutic range, there would be a need of 
administration of drug for more than once a day. Patients with multiple drug regimens 
and with several dosing intervals are usually non-compliant with the therapy. There is 
also a fluctuation observed in case of multiple dosing of a drug. The therapeutic effect 
cannot be achieved. 
The solution for this is achieved by the Sustained release formulations where the 
release of drug is manipulated in such a way that the concentration of drug will be in 
the therapeutic window for longer durations than the conventional drug delivery 
systems. 
There are several advantages that make sustained drug delivery a choice of drug 
delivery systems: 
 The therapeutic effect of drug can be enhanced at lower concentrations. 
 The adverse effects can be minimized. 
 Frequency of dosing can be minimized. 
 Improvement of patient compliance. 
The release of drug form a system can be controlled either13 
  By forming a Membrane around10 the Dosage form that sustains the release 
of drug by forming a layer that retards the release form the core. Polymers are 
employed, in forming the membrane around the dosage form. Polymeric membrane 
can be a Micro-porous, Non-porous or a semi-permeable membrane. A polymer like 
Ethylene-vinyl acetate copolymer is found to be used in many formulations as 
polymer membrane to control the release in several products. 
   The equation13 that explains several variables that influence release from this kind of 
system: 
 
 
                        
Where Km/r and Ka/m are, respectively, the partition co-efficients for the 
interfacial partitioning of drug molecules from the reservoir to the membrane and 
from the membrane to the aqueous diffusion layer; Dm, and Dd are, respectively, the 
diffusion coefficients in the rate-controlling membrane with a thickness of hm, and in 
the aqueous diffusion layer with a thickness of hd. 
 
  Another technique of controlling the rate of drug from the dosage is by 
forming a matrix around the drug molecules with Lipophilic or Hydrophilic 
polymers. This can be achieved by dispersion of the drug particles blend in the 
semisolid polymer and then cross-linking of the polymer chains. By Kneading the 
polymer with the drug particles well that forms a matrix on contact with the water 
(Hydroxy Propyl Methyl Celluloses).   Melt extrusion is also used in fabricating the 
polymer matrix systems. 
          The equation that explains several variables that influence release from this kind 
of system: 
 
 
 In which the time-dependent thickness [ha(t)] of the diffusional path for drug 
molecules to diffuse through, which is increasing with time, is compensated by the 
proportional increase in the drug-loading level [Cp(ha)],and a constant drug release 
profile is thus obtained. 
 
  A technique includes the combination of both the Membrane permeation 
system and Matrix systems. The core would be a matrix comprising of Polymer 
matrix and the   membrane is employed for further regulation of drug release. 
The equation that explains several variables that influence release from this kind of 
system: 
 
 
 
where A is the initial amount of drug solid impregnated in a unit volume of 
polymer matrix with solubility Cp and diffusivity Dp; Km is the partition coefficient 
for the interfacial partitioning of drug molecules from polymer matrix toward polymer 
coating membrane; Pm is the permeability coefficient of the polymer coating 
membrane with thickness hm; and Pd is the permeability coefficient of the 
hydrodynamic diffusion layer with thickness hd 
 
 Micro-reservoir systems are another way regulating the release of the drug 
from the dosage forms. This includes fabrication of several micro-reservoirs, by 
dispersing solid drug particles in a water miscible polymer and again dispersing this 
matrix in another polymer that forms several micro-reservoirs which is bio-compatible 
in nature. 
The equation that explains several variables that influence release from this kind of 
system: 
 
  
 
 
  Where m = a/b and n is the ratio of drug concentration at the inner edge of the 
interfacial barrier over the drug solubility in the polymer matrix,[1,6] in which a is the 
ratio of drug concentration in the bulk of elution solution over drug solubility in the 
same medium and b is the ratio of drug concentration at the outer edge of the polymer 
coating membrane over drug solubility in the same polymer and S1 and Sp are the 
solubility of the drug in the liquid compartments and in the polymer matrix, 
respectively. 
     A drug molecule that is having high solubility, small elimination half-life, 
which is usually administered for more than once a day is suitable for formulating in 
to a sustained release formulation.  
Conclusion: 
 Keeping everything in a nutshell, it can be noted that Bi-layered tablets can be 
an ideal carrier for drugs that are usually prescribed in Combinational therapy.  
Thiazolidinedone and Biguanides are suitable candidates for Bi-layered tabletting. As 
Biguanides usually have shorter half life and are administered for more than three 
times a day, Biguanide is selected as drug candidate for sustained release layer. 
Thiazolidinediones are having higher half-lives and so selected as drug candidate for 
immediate release layer in the Bi-layered tablets 
 
 
2. OBJECTIVE AND PLAN OF WORK 
 
AIM: 
 The aim of the work is to design and develop Bi-layered matrix tablets 
comprising of a Thiazolidinedione derivative in the immediate release layer and a 
Biguanide in the Sustained release layer and to carry out the In vitro release study of 
the drugs. 
The objectives which were destined to achieve during the work are:  
¾ Bi-layered tablets with good physical strength. 
¾ Tablets with correct content of active pharmaceutical ingredients 
without variation. 
¾ To obtain optimal sustained release of the drug in the First layer and 
optimal release from the Immediate release layer. 
PLAN OF WORK: 
¾ Literature survey 
¾ Pre-formulation studies:  
API characterization and  
Drug-Excipients compatibility studies.  
¾ Optimization of the formula that results all the desired physical 
characteristics. 
¾ Pre-Formulation analysis like  
1. Angle of repose 
2. Bulk density 
3. Tapped density 
4. Compressibility index 
5. Hausner’s ratio 
¾ Post- Compression analysis of tablets to know the parameters like 
Hardness, Uniformity of weight, Dimensions, %Friability, and amount 
of drugs in the units. 
¾ In vitro dissolution study and  
¾ Analysis of data to know the kinetic pattern of the drug. 
¾ Stability studies to be done on the optimized formula at two conditions 
45°C/75% RH and 30°C/65%RH. 
 
 
 
3. LITERATURE REVIEW 
  Naeem et al 11developed and characterized bi-layered tablets of Tramadol 
HCl and Acetaminophen micro particles in which they have used 
Ethylcellulose as drug release retarding polymer. The micro particles were 
prepared separately and were compressed as Bi-layered tablets. The release of 
drug was observed for 8 hours and 12 hours where the formulations followed 
Higuchi’s pattern of controlled release. Although a conventional solid dosage 
combination of TmH and AAP has been approved by the United States Food 
and Drug Administration (FDA) for use, patients still have to take the 
conventional tablets 3 - 4times a day. To improve patient’s compliance, a 
controlled-released combination was developed and characterized in this study 
for its physical and chemical stability as well as for release characteristics.  
 Laxmi Goswami et al 12. Formulated and evaluated Bi-layered floating tablets 
of two anti-diabetic drugs to increase the gastric residence time of a drug in 
one layer and to release another drug immediately from second layer. They 
have carried out the work by using HPMC, Carbapol, Polyvinylpyrrolidone as 
chief ingredients. The formulated tablets were subjected for In vitro studies 
which were carried out in USP Type II apparatus. The tablets were found to be 
buoyant for 12-20 hrs.  
 Durga Prasad Pattanayak et. al.13 formulated bilayered tablets comprising 
Metformin and Glimipride, where they have optimized the blends of both the 
layers separately. They have used HPMC and Polyethylene oxide for 
sustaining the drug release for about 24 hours. Form the stability profile they 
have concluded that HPMC based formulations are found to be giving better 
release profile than that of PEO. Those formulations also exhibited Zero-order 
release kinetics.  
 Bhala chirag et al 14. Formulated and evaluated bilayered tablets of two 
model Anti-Diabetic drugs by using HPMC K 4M for sustained release layer 
and Croscaramellose Sodium for Immediate release layer. the work suggests 
that the increase concentration of the polymer brought about the sustained 
release effect of drug in the Sustained release layer. They have used wet 
granulation for sake of sustained release layer and direct mixing for immediate 
release layer. The sustained release followed Higuchi’s kinetic pattern. Thay 
have concluded that Bi-layered tablets can be a good alternative for 
conventional tablets of the model Anti-Diabetic drugs.  
 Dhaval Patel et.al.15 formulated and evaluated Bi-layered floating tablets for 
Gastric retention of Ciprofloxacin HCl. Both the layers were prepared by 
direct compression. HPMC K 15M and Carbapol 934P were used for sustained 
release of drug. Sodium bicarbonate was used for producing the floating 
effect. Sodium starch glycolate was used for immediate release layer. They 
have concluded that Carbapol 934 P and HPMC K 15M gave a desired kinetic 
profile for the Immediate release layer and Sodium bicarbonate produced 
optimum Lag time for obtaining the release profile for 12h.  
 Pankaj et al16. designed and developed a Bi-layered tablets formulation of 
Simvastatin. HPMC (104) was used for the sake of Suatined release layer and 
Croscaramellose sodium and Sodium starch glycolate for the immediate 
release layer. They have concluded that Bi-layered tablets are good 
application for sustaining the drug release and also releasing the drug 
immediately from a single dosage form.  
 Preeti Karwa et al17 designed and evaluated the release of the Bi-layered 
tablets of Zolpidem Tartarate. HPMC K 100M was used for retarding the 
release in the sustained release layer and Croscaramellose sodium for the 
sake of immediate release in the immediate release layer. HPMC K 100M 
was found to be retarding the release of the drug for 6 hours. The release 
profile was found to be fitting Korsmeyer-Peppas kinetic model and Quasi-
Fickian diffusion.  
  Mohana Raghava Srivalli et al18. designed novel Bi-layered gastric muco-
adhesive systems for localized and unidirectional release of Lamotrigine. 
Carbapol 974 p and Polyox were used for Muco-adhesion and HPMC K 15M 
was used for control release of the drug. The formulations were evaluated for 
the exvivo mocoadhesion and also for In vitro release of the drug. The 
formulations were found to be giving optimal muco-adhesion and also 
controlled release. It was also concluded that uni-directional release of the 
drug is possible.  
 Sharad  Darandale et. al19 designed and characterized a Gastroretentive 
dosage form consisting of Furosemide.  The dosage consists of two layers in 
which one layer is controlled release formulation (CR layer) and an IR layer. 
These are muco-adhesive films that are placed in capsule, adhere to mucosa 
after swelling. Controlled release of the drug was brought by the 
Hydroxypropyl β-cyclodextrins in both layers and Carbapol 971P in CR layer. 
Optimum release, Bio-adhesion and mechanical properties were also the 
result of incorporation of these polymers. 
 Kiran musle et al20 designed and formulated Bi-layered tablets of 
Paracetamol and Diclofenac sodium, where the former drug in immediate 
release layer and latter in to sustained release layer. HPMC K 4M was used as 
release rate retard agent. It is stated that for combiaton therapy Bi-layered 
tablets are better alternatives for multiple drug dosage form intake. 
 Rajendran et al21. formulated and evaluated Bi-layered tablets of  Anti-
diabetic drugs in which one drug is incorporated in sustained release layer for 
prolonged effect by using HPMC K 100M and HPMC K 100M as rate 
retardants of release of the drug. Second layer is an immediate release layer 
with Croscaramellose sodium and Sodium starch glycolate as 
Superdisintegrants. The formulations comprising HPMC K 100M and HPMC 
K 15M in combination were fopund to be giving optimum release profile for  
drug in sustained release layer. The release of the drug is observed up to 8 
hours. The release profile fits in to Higuchi’s kinetic model for drug release.  
 Mohammed Mofizur Rahman et al22 formulated and evaluated matrix tablets 
of Ranolazine with Eudragit L 55 100 and with different viscosity grades of 
HPMC polymers (Methocel E50 and Methocel K 15M CR). The dissolution 
study was done 2h in simulated gastric fluid and for 6h in pH 6.8 phosphate 
buffer. It was stated that by increasing the concentration of polymers, there 
was a decrease in the rate of release of the drug. Further it was found that the 
release from formulations containing Eudragit L 55 100 and high viscosity 
grades of HPMC is slower than that of the low viscosity grades of HPMC 
(Methocel E50).  
  Maggi et al23 studies compared the capabilities of PEO with two different 
grades of HPMC polymers in case rate controlling of drug release. They have 
employed these polymers in different polymers where only the concentrations 
are varying by having other parameters constant. They concluded that HPMC 
polymers retarded the release of drug better that of PEO polymers.  
 
 Mohamed Halith et al24 formulated Bi-layered tablets of Amlodipine Besilate 
and Metoprolol Succinate by having the former in the SR layer and the latter 
in IR layer. HPMC was used as release retardant and Sodium Starch Glycolate 
as superdisintegrant. The release of drug in the SR layer was studies for 20 
hrs. It was found to be following Zero-order kinetics. 
 Patel Naveen et. al.25 designed and formulated Floating matrix tablets of 
Metoprolol Tartrate in a view of increasing its gastric residence time. HPMC 
K 100M was used as release retarding agent. It was concluded that the 
formulations with higher percentages of HPMC K 100M decreased the release 
rate of the drug than the formulations with HPMC K100M in lower 
percentages.  
 Beatriz Luna et. al .26 have suggested in their article that combination of a 
Biguanide and Thiazolidinedione derivatives for a synergestic action in 
control of elevated Glucose levels. It was suggested that this combinational 
therapy is advised when there are no predicted results from single Oral Anti-
Diabetic agent.  
 Patel Mehul27 reviewed challenges in formulation of Bi-layered tablets. It 
was suggested that Bi-layered tablets are purpose-built Bi-layered tablet 
presses are of good choice to preclude several problems during manufacturing 
process like Layer separation, insufficient hardness, and inaccurate weight 
control of individual layers and cross contamination. It was concluded that 
whenever high-quality bi-layer tablets need to be produced at high speed, the 
use of an ‘air compensator’ in combination with displacement control appears 
to be the best solution. The sensitivity of the displacement-based control 
system increases as pre-compression force decreases, resulting in a higher 
accuracy.  
 Kumara Swamy et. al.28 formulated and evaluated the Oro-dispersible tablets 
of Theophylline using various superdisintegrants. Oro-dispersible tablets were 
prepared with superdisintegrants Crosscaramellose sodium, Crosspovidone, 
Sodium starch glycolate with concentarations 2%, 3% and 5%.  Formulations 
with 5% superdisintegrants have shown good disintegrant effects. 
Formulations with Croscaramellose Sodium and Crosspovidone have shown 
good dissolution profiles and less disintegration time. 
  
MATERIALS USED FOR STUDY 
MATERIAL SOURCE 
API I Wanbury limited 
API II Biocon limited 
Hydroxypropyl Methycellulose K 100M DOW chemicals / Colorcon Asia 
Hydroxypropyl Methycellulose 15CPS Taian Ruitai Cellulose Co., Ltd 
Croscaramellose sodium DMV Fonterra Ltd. 
Sodium Carboxy Methyl Cellulose Pioma Chemicals 
Di-Basic Calcium Phosphate Sudeep pharma 
Povidone BASF Ltd. 
Low-substituted Hydroxy Propyl Cellulose Aqualon Ltd 
Lactose DMV Fonterra Ltd. 
Colloidal Silicon Dioxide Wacker Silicones 
Talc Luzenac Ltd. 
Indigo Caramine Lake Roha dye chem.. 
Magnesium stearate Amishi drugs and chemicals 
 
 
 EQUIPMENTS USED FOR THE STUDY 
INSTRUMENTS MAKE 
Top loading balance Sartorius 
Rapid Mixer Granulator Allen-Bradley 
Octagonal Blender PAM Machineries 
Rapid Dryer Retsch T-200 
8-station Bi-layer Tablet Press  Rimek 
Mechanical Stirrer Remi Motor  
Tap density testing apparatus Electrolab 
Hardness tester Schleuniger 8M Tablet tester 
Friability testing apparatus Electrolab 
Disintegration time testing apparatus Electrolab 
Moisture Balance Sartorius 
Analytical Balance Sartorius 
Dissolution apparatus 
Lab India 
Disso 2000 
High Performance Liquid Chromatography SHIMADZU LC 2010 C HT 
FTIR IR PRESTIGE 21 
API I29, 30, 31 
Category  : Oral Anti-Hyperglycemic drug. 
Description  : White crystalline powder. 
BCS classification : Class III drug. 
 
Physico-chemical properties 
Solubility  : Freely soluble in water, slightly soluble in ethanol, Insoluble  
                                                   in Acetone, Chloroform  
pKa    : 12.4 
 
Mechanism of action: Decreases blood glucose levels by decreasing hepatic glucose  
                                       production, decreasing intestinal absorption of glucose, and  
                                       improving insulin sensitivity by increasing peripheral glucose  
                                       uptake and utilization. These effects are mediated by the initial  
                                       activation by of AMP-activated protein kinase (AMPK), a liver  
                                       enzyme that plays an important role in insulin signaling, whole  
                                       body energy balance, and the metabolism of glucose and fats.  
                                       Activation of AMPK is required for the drug’s inhibitory effect on  
                                       the production of glucose by liver cells. Increased peripheral  
                                       utilization of glucose may be due to improved insulin binding to                          
                                       insulin receptors. Its administration also increases AMPK activity  
                                       in skeletal muscle. AMPK is known to cause GLUT4 deployment  
                                       to the plasma membrane, resulting in insulin-independent glucose  
                                       uptake 
 
 
 
Pharmacokinetics  
Absorption    : Absorbed over 6 hours, bioavailability is 50 to 60% under fasting  
                                         conditions. Administration along with food decreases and delays    
                                          absorption. 
Volume  
of Distribution    : 654 L for 850 mg administered as a single dose. The  
                                          volume of distribution following IV administration is 63-276 L,     
                                           likely due to less binding in the GI tract and/or different methods  
                                           used to determine volume of distribution. Peak action occurs 3  
                                           hours after oral administration. 
 
Excretion  : Approximately 90% of the drug is eliminated in 24 hours in those  
                                      with healthy renal function. Renal clearance of the drug  is  
                                      approximately 3.5 times that of creatinine clearance, indicating the  
                                      tubular secretion is the primary mode of elimination. 
Half-life  : 6.2 hours. Duration of action is 8-12 hours. 
 
Dosage  : The maximum recommended daily dose in adults is 2000 mg. 
 
Indications  : For use as an adjunct to diet and exercise in adult patients (18 years  
                                      and older)  with NIDDM. May also be used for the management of  
                                      metabolic and  reproductive abnormalities associated with polycystic  
                                       ovary syndrome (PCOS). 
Side effects               : Diarrhoea, Nausea, Gas, Weakness and indigestion are some of the  
                                    side effects. 
 
 
API-II29, 30, 31 
Category   : Oral Anti-Hyperglycemic drugs. 
BCS Classification : Class IV drug 
Description  : White crystalline powder. 
Dosage  : 15mg and 30mg upto 45mg 
Solubility  : Practically insoluble in water, ether. Soluble in Di-methyl 
formamide,  
                                      very  slightly soluble in Acetonitrile. 
 
Mechanism of action: This acts as an agonist at peroxisome proliferator activated  
                                       receptors (PPAR) in target tissues for insulin action such as adipose  
                                       tissue, skeletal muscle, and liver. Activation of PPAR-gamma  
                                       receptors increases the transcription of insulin-responsive genes  
                                       involved in the control of glucose production, transport, and  
                                      utilization. In this way, it both enhances tissue sensitivity to  
                                      insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance  
                                       associated with type 2 diabetes mellitus is improved without an  
                                       increase in insulin secretion by pancreatic β cells. 
Pharmacokinetics 
Absorption  : Following oral administration, in the fasting state, it is first  
                                       measurable in serum within 30 minutes, with peak concentrations   
                                       observed within 2 hours. Food slightly delays the time to peak serum   
                                       concentration to 3 to 4 hours. 
Volume of distribution: 0.63 ± 0.41 L/kg. 
Metabolism     : This undergoes Hepatic metabolism. 
  
Excretion     : This is found to be eliminated unchanged by the Biliary excretion.  
                                         The renal excretion is said to be negligible. 
Half-Life     : 3-7 hours. 
 
Indications              : Treatment of Type II diabetes mellitus. 
Side effects                 : Sore throat, weight gain, muscle pain, tooth problems are likely to  
                                        occur. 
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DIBASIC‐CALCIUM PHOSPHATE 
Synonyms:    A‐TAB;  calcium  monohydrogen  phosphate;  calcium 
orthophosphate;  Di­CafosAN;  Dicalcium  orthophosphate;  E341; 
Emcompress  Anhydrous;  Fujicalin;  phosphoric    acid  calcium  salt  (1 : 1); 
secondary calcium phosphate. 
Structural Formula: CaHPO4   
Category: Tablet and capsule diluent. 
Description: Anhydrous  dibasic  calcium  phosphate  is  a white,  odorless, 
tasteless powder or Crystalline solid. It occurs as triclinic crystals. 
Solubility:  Practically  insoluble  in  ether,  ethanol,  and  water;  soluble  in 
dilute acids. 
Handling Precautions: Observe  normal  precautions  appropriate  to  the 
circumstances  and  quantity  of  material  handled.  The  fine‐milled  grades 
can generate nuisance dusts and the use of a respirator or dust mask may 
be necessary. 
Storage Conditions: The bulk material should be stored in a well-closed container in 
a dry  place. 
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COLLOIDAL SILICON DIOXIDE 
Synonyms:  Aerosil;  Cab‐O‐Sil;  colloidal  silica;  fumed  silica;  light 
anhydrous                       silicic acid; silicic anhydride; silicon dioxide fumed. 
Structural Formula: SiO2 
Functional  Category:  Adsorbent;  anticaking  agent;  emulsion  stabilizer; 
glidant; Suspending  
                                         agent;  tablet  disintegrant;  thermal  stabilizer; 
viscosity‐increasing agent. 
Description:  Colloidal  silicon  dioxide  is  a  submicroscopic  fumed  silica 
with a particle size of                         about 15 nm. It is a light, loose, bluish‐
white‐colored, odorless,  tasteless,                                                                              nongritty 
amorphous powder. 
Solubility: Practically insoluble in organic solvents, water, and acids, except hydrofluoric                   
acid; soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersionwith water. 
Handling  Precautions:  Eye  protection  and  gloves  are  recommended. 
Precautions should be taken to avoid inhalation of colloidal silicon dioxide. 
In the absence of suitable                            containment facilities, a dust mask 
should be worn when handling small                          quantities of material. 
For  larger  quantities,  a  dust  respirator  is  recommended.  Inhalation  of 
colloidal silicon dioxide dust may cause  irritation to  the respiratory  tract 
but  it  is  not  associated  with  fibrosis  of  the  lungs  (silicosis),  which  can 
occur upon exposure to crystalline silica. 
Storage Conditions: Colloidal silicon dioxide powder should be stored in 
a well‐closed                                        container. 
 
 
TALC 
Synonyms:  Altalc;  Hydrous  magnesium  calcium  silicate;  Hydrous 
magnesium silicate;                      Magnesium hydrogen metasilicate; Magsil 
Osmanthus; Powdered talc; Purified                                            French chalk; Purtalc; 
Soapstone; Steatite. 
Structural Formula: Mg6 (Si2O5)4(OH) 4 
Description:  Talc  is  a  very  fine,  white  to  grayish‐white,  odorless, 
impalpable, unctuous,                          crystalline powder. It adheres readily 
to the skin and is soft to the touch and free                          from grittiness. 
Functional  Category:  Anticaking  agent;  glidant;  tablet  and  capsule                                
lubricant. 
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Handling Precautions: Observe  normal  precautions  appropriate  to  the 
circumstances and                                                   quantity of material handled. Talc  is 
irritant if inhaled and prolonged excessive                                                exposure may 
cause  pneumoconiosis.  In  the  UK,  the  occupational  exposure  limit                          
for  talc  is  1 mg/m3  of  respirable  dust  long‐term  (8‐hour  TWA).  Eye 
protection,                    gloves, and a respirator are recommended. 
Storage Conditions: Talc should be stored in a well‐closed container in a cool, dry place. 
 
 
MAGNESIUM STEARATE 
Synonyms:  Magnesium  octadecanoate;  octadecanoic  acid,  magnesium 
salt; stearic acid,  magnesium salt. 
Structural Formula: [CH3 (CH2)16COO] 2Mg 
Description: Magnesium stearate is a very fine, light white, precipitated or 
milled,  impalpable  powder  of  low  bulk  density,  having  a  faint  odor  of 
stearic acid and a characteristic   taste. The powder is greasy to the touch 
and readily adheres to the skin. 
Functional Category: Tablet and capsule lubricant 
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly soluble                                 
in warm benzene and warm ethanol (95%). 
Handling Precautions: Observe  normal  precautions  appropriate  to  the 
circumstances and quantity of material handled. Eye protection and gloves 
are  recommended. Excessive  inhalation of magnesium stearate dust may 
cause  upper  respiratory  tract  discomfort,  coughing,  and  choking. 
Magnesium stearate should be handled in a  well‐ventilated environment; 
a respirator is recommended. 
Storage Conditions: Magnesium stearate is stable and should be stored in a well-
closed  container in a cool, dry place. 
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EVALUATION OF ACTIVE PHARMACEUTICAL INGREDIENTS33, 34: 
The active pharmaceutical ingredients to be used were analysed to know several 
physico-chemical properties during pre-formulation stage. They are; 
1) Solubility. 
2) Bulk density. 
3) Tapped density. 
4) Carr’s index. 
5) Hausner’s ratio. 
6) Loss on drying. 
7) Assay 
 
Solubility: 
Solubility of the substance is determined by adding 1 gram each of the APIs to 
different quantities of solvent, as the solubility of solute depends on the type of solvent used. 
Several solvents were used (Water, Methanol, Chloroform, Acetone, Ethyl acetate). The 
solubility of API is reported by using the specifications of IP i.e. in the following manner. 
 
 
 
 
                             Table 2 Description of solubility                                                  
Descriptive terms Parts of solvents for 1 part of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble More than 10,000 
 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore.  Page 40 
 
Bulk density: 
Bulk density is mass of the powder per Bulk volume of the drug. Bulk density is 
determined by filling the graduated measuring cylinder with 50 grams of APIs and noting 
down the volume occupied by them. It is calculated by using the formula; 
Bulk density   =     Mass of the powder  
                               Bulk volume of powder  
Tapped density: 
Tapped density is the ratio between a given mass and the volume of the powder after 
tapping for some fixed number of taps. Electrolab tapped density tester is used for 
determining the tapped density of the powder for 750 taps. Tapped density is found from the 
formula: 
 Tapped density =    Mass of the powder  
                                Tapped volume of the powder 
Carr’s index: 
The flow property of the APIs is can be inferred from the value of Compressibility 
index or Carr’s index. This can be measured from the Bulk density and Tapped density.  
CI =        (Tapped density – Bulk density)           × 100   
                          Tapped density 
When the values of CI are less than 15%  the powder possesses good flow properties 
and when it is more than25% it indicates poor flow. 
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Hausner’s ratio: 
It is ratio of Tapped density and the Bulk density. It is a measure of the frictional 
resistance of the drug. The ideal range of Hausner’s ratio is 1.0-1.18. 
Hausner’s ratio = Tapped density / Bulk density 
Loss on drying: 
This gives the moisture content of the powder. It is determined by testing the APIs at 
a temperature of 105°c for 5 minutes in Sartorius Moisture testing apparatus. The ideal 
moisture content must be 0.5% for both the APIs.  
Assay: 
 For API I:  
60 mg of API is weighed accurately and dissolved in 4ml of anhydrous formic acid. 
This is added with acetic anhydride. 0.1M Perchloric acid is used for titration. The end point 
is determined potentiometrically. Calculate the content of API I 
The content of drug should be in the range 98.5 – 101.0 percent. 
For API II: 
For API II, the assay is done using Liquid Chromatography. The conditions for study 
were given below 
Column: 25 cm × 4.6 cm stainless steel column packed with Octadecylsilane-porous silica  
               -(5µ) 
Mobile phase: 50 volumes of 0.01M Potassium dihydrogen phosphate and 50 volumes of   
Acetonitrile  
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Column temperature: 25°C 
Flow rate: 1 ml/min. 
Inject volume: 20µl.  
Wavelength: 225 nm. 
 The standard and sample were injected and the amount of drug can be calculated from 
area of the peak obtained. The content should be in the range of 98.0 – 102.0 percent. 
Standard preparation: 
 A 0.03% w/v solution of API II RS in methanol. Dilute 1 ml of reference solution to 
100 ml with methanol. 
Sample preparation: 
 Dissolve 30 mg of the substance under examination in 100 ml of methanol.  
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Drug-Excipient Compatibility study35: 
 The successful formulation of a stable and effective dosage form depends on the 
careful selection of the excipients that are added to facilitate administration, promote the 
consistent release and Bioavailability of the drug and protect it from degradation. The 
excipients are selected by conducting compatibility studies with the APIs. 
Procedure: 
The APIs were mixed with some of the excipients that can be used for formulation in 
the ratio given in the Table. These are placed in stability chambers at conditions 25°C/60% 
RH and 40°C/75% RH for 30 days. The samples that were placed in 40°C/75%RH chambers 
were analysed with Infra-Red spectroscopy after 30 days. For IR studies Shimatzu FTIR (IR 
Prestige 21) was used.      
The IR spectroscopy graphs obtained were compared with standard graphs. Any 
possible interactions can be detected from changes in graphs of IR studies. The excipient that 
is causing a change will not be used in the formulation. 
Containers: 
¾ Containers and closures for the compatibility study are 10 ml flint glass vials 
(USP Type I), Bromo butyl rubber stoppers and tears off clear lacquer 
aluminium seals. 
¾ Remove vials from packaging and sort out the vials with defects like cracks, 
broken edges, air bubbles and reject them form using. 
¾ Clean the vials by rising initially with potable water followed by rinsing with 
purified water. 
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¾ Dry the washed vials in hot air oven (70°C for 1hour). Physically sort the 
washed and dried vials for any kind of defects like broken edges, cracks or air 
bubbles, white or black fibres/particles, foreign matter, etc and reject those 
vials. 
Sample preparation: 
 Binary mixture of drug and excipients as per the ratio mentioned in Table 3 were 
prepared and placed with accurate amount of drug and excipient in a polybag and mixed. 
Then these samples were placed in separate flint glass vials. Then these samples were 
charged in stability chamber of conditions 40°C/75%RH and 25°C/60%RH. 
 After 15days and 30 days, samples were also seen for changes in the colour and  
odour (samples placed in both the conditions).  
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Particulars Ratio Description 
Parameters 
Initial 
25°C/60%RH 40°C/75%RH 
15  
days 
30  
days 
15  
days 
30  
days 
API 
I 
Dry 
- 
White 
crystalline 
powder and 
mass 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Aqueous 
Non-
aqueous 
API 
II 
Dry  
- 
White 
crystalline  
powder and 
mass 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Aqueous 
Non-
aqueous 
API I    +  API II 2:1 White  powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I +  
HPMC K 4M 1:1 
White 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I +  
HPMC K 15M 1:1 
White 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I +  
HPMC K 100M  1:1 
white 
powder 
mixture 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observatio
n 
API I + 
 HPMC 15 CPS 
  
1:0.25 
White 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + S-CMC 1:0.50 
 white 
powder 
mixture 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + Lactose 
monohydrate 1:1 
White 
powder  
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + Dibasic 
Calcium 
           phosphate 
1:0.50  white powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + Povidone 1:0.25 
White 
powder 
mixture 
Physical 
observation 
Physical 
observation 
Physical 
obseLactoser
vation 
Physical 
observation 
Physical 
observation 
API I + Colloidal 
silicon dioxide 1:0.25 
White 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + Talc 1:0.25 White powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API I + 
Magnesium 
stearate 
1:0.25 White powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API II + L.S. HPC 
(LH- 11) 1:1 
Off white 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
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(.....continued) 
 
Table 3 Parameters to be checked for Compatibility studies of Drug and excipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particulars Ratio Description 
Parameters 
Initial 
25°C/60%RH 45°C/75%RH 
15  
days 
30  
days 15 days 30 days 
API II + CCS 1:1 
Off white 
powder 
Mixture 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API II + Indigo 
caramine lake 1:0.50 
Sky blue 
coloured 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API II + Talc 1:0.5 
White 
coloured 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
API II + 
Magnesium 
Stearate 
1:0.5 
White 
coloured 
powder 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
Physical 
observation 
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FORMULATION TRIALS 
 To develop an optimum formula for the Bi-layered tablets, several trials were done. 
The general procedure for preparation of  both the layers in all the trials is given below.  
Procedure for LAYER I: 
1. Dispensing: Materials required are dispensed in separate poly bags and are kept ready for 
sifting. 
2. Sifting:   Materials are sifted to obtain uniform sized particles and improve the mixing. 
API-I, Polymer (HPMC K 4M or HPMC K 15M or HPMC  ) S-CMC, HPMC 15CPS, Di-
calcium phosphate, Colloidal Silicon Dioxide are sifted through 40# mesh. Magnesium 
Stearate and Talc were sifted through 60# mesh. 
3. Binder solution: binder solution is prepared by mixing Povidone in sufficient quantity of 
hot water. 
4. Dry mixing: materials are loaded in RMG and are mixed for about 10 minutes at slow 
speed. 
5. Granulation: Binder solution is added for three minutes at slow speed. After the addition 
of the binder, it is mixed for about three minutes.  
6. Wet milling:  the wet mass is milled in a Multi-mill using a 2 mm screen and the mass is 
subjected for drying. 
7. Drying: Blend of above step is loaded in a rapid dryer at a temperature of 500 C with 
airflow of 50. Drying continued until the Loss on Drying reaches a range of 1.5% to 2%. 
8. Sifting: The blend of above step is subjected to milling with final screen of   1.5 mm and 
th blend is subjected for Pre-lubrication. 
9. Pre-lubrication: Colloidal Silicon Dioxide and HPMC K 100M** sifted and kept aside in 
the Sifting step is added to the blend and blended in an Octagonal blender for 5 minutes.  
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10. Lubrication: Talc and Magnesium stearate sifted in 60 # Screen were added to the blend 
and mixed for 2 minutes. 
**Only in Trials 6 & 7. 
Procedure for LAYER II: 
1. Dispensing: Materials required are dispensed in separate poly bags and are kept ready for 
sifting. 
2. Sifting:   Materials are sifted to obtain uniform sized particles and improve the mixing. 
API-II, LS-HPC, Lacotse DCL 15, Croscarmellose Sodium are  sifted through 40# sieve. 
Indigo Caramine Lake is sifted through 100 # sieve. Magnesium stearate and Talc were 
sifted through 60# mesh. 
3.  Dry Mixing: API II is mixed with Lactose DCL 15 of second step geometrically for 
uniform mixing and then with other materials. The mixing is done for about 30 minutes in 
an Octagonal Blender.  
4. Lubrication: Lubrication is done using the Talc and Magnesium Stearate sifted with 60# 
sieve before for 2 minutes. 
Blend obtained is compressed along with blend of Layer I.  
COMPRESSION: Compression is carried out in Bi-layered tablet press. The punches 
selected were 20.5x 9.5 mm punches. Physical parameters like Hardness, Thickness, 
Length and Width are controlled as per required and noted. 
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Table 4 Process Flow Chart 
 
(Layer I)  
(Extended Release Layer) 
   
(Layer II) 
(Immediate Release Layer) 
 ↓                            ↓                       
Dispensing   Dispensing 
 ↓                            ↓                       
Sifting   Sifting 
                         ↓                                     ↓ 
Dry mixing of drug, polymer    
and excipients 
  Dry mixing of drug and 
excipients 
↓                 
 
Wet granulation 
 
    
Drying    
    
Pre lubrication      
 ↓                                      
Lubrication   Lubrication 
↓                                       
Compression   Compression 
    
 
 Bilayer Tablet  
 ↓  
 Polyvinyl chloride 
(PVC) Blister Packing
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TRIAL-1 (F1) 
AIM: To take a feasibility trial of Bi-layered tablets comprising SR layer and IR layer of 
API-I and API-II using HPMC K4M as polymer for sustaining release of API-I. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Oral Anti hyperglycemic 856.00 
2 HPMC K4M  Release retarding polymer 170.00 
3 Sodium Carboxy methyl cellulose Channelling agent 35.00 
4 Di-calcium phosphate Diluent 19.50 
5 Polyvinlypyrrolidone (Povidone) Binder 7.50 
6 Purified water Granulating solvent q.s. 
 Extra granular material   
7 Colloidal silicon dioxide Glidant 8.00 
8 Talc Glidant 4.00 
9 Magnesium Stearate Lubricant 4.00 
 Total  1100 
Table 5 Formula for (F-1) Layer I 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic  7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 62.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  100 
Table 6 Formula for F-1 Layer II 
 
 
. 
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TRIAL-2 (F2) 
AIM: To take a trial batch of Bi-layered tablets as Trial 1, but by replacing the HPMC K4M 
with HPMC K15M to retard the release in Layer I and increasing the amount of Binder and  
Diluent in Layer II. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Oral Anti hyperglycemic 856.00 
2 HPMC K15M  Release retarding polymer 170.00 
3 Sodium Carboxy methyl cellulose Swelling agent, channelling agent 35 
4 Di-calcium phosphate Diluent 11.00 
5 Polyvinlypyrrolidone (Povidone) Binder                  8.00 
6 Purified water Granulating solvent q.s. 
 Extra granular material   
7 Colloidal silicon dioxide Glidant 8.00 
8 Talc Glidant 4.00 
9 Magnesium stearate Lubricant 8.00 
 Total  1100 
Table 7 Formula for F-2 Layer I 
• HPMC K4M is replaced with HPMC K15M. 
• Increase the amount of binder to improve hardness. 
• The amount of Lubricant is doubled to avoid the sticking observed in compression 
during Trial 1. 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II  Anti- oral hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 8 Formula for F-2 Layer II 
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TRIAL-3 (F3) 
AIM: To take a trial batch of Bi-layered tablets as Trial 2, but by replacing the HPMC K15M 
with HPMC K100M at lower amount to retard the release in Layer I and increasing the 
amount of Binder. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Oral Anti hyperglycemic 856.00 
2 HPMC K100M  Release retarding polymer 100.00 
3 Sodium Carboxy methyl cellulose  Channelling agent 35.00 
4 Di-calcium phosphate Diluent 80.00 
5 Polyvinlypyrrolidone (Povidone) Binder 9.00 
6 Purified water Granulating solvent q.s. 
 Extra granular material   
7 Colloidal silicon dioxide Glidant 8.00 
8 Talc Glidant 4.00 
9 Magnesium stearate Lubricant 8.00 
 Total  1100 
Table 9 Formula for F-3 Layer I 
• HPMC K15M is replaced with HPMC K100M. 
• The amount increase of binder to improve hardness. 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 10 Formula for F-1 Layer II 
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TRIAL-4 (F4) 
AIM: To take a trial batch of Bi-layered tablets as Trial 3, but by addition of HPMC 15 CPS 
to retard the release in Layer I and increasing the amount of Binder. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Oral Anti hyperglycemic  856.00 
2 HPMC K100M  Release retarding polymer 100.00 
3 HPMC 15 CPS Synergises the polymer effect 15.00 
3 Sodium Carboxy methyl cellulose Channelling agent 35.00 
4 Di-calcium phosphate Diluent 64.00 
5 Polyvinlypyrrolidone (Povidone) Binder 10.00 
6 Purified water Granulating solvent q.s. 
 Extra granular material   
7 Colloidal silicon dioxide Glidant 8.00 
8 Talc Glidant 4.00 
9 Magnesium stearate Lubricant 8.00 
 Total  1100 
Table 11 Formula for F-4 Layer I 
• HPMC 15CPS is added along with HPMC K100M to improve sustained release of 
API I. 
• Increase the amount of binder to improve hardness. 
 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 12 Formula for F-4 Layer I 
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TRIAL-5 (F5) 
AIM: To take a trial batch of Bi-layered tablets similar to Trial 4, but by increasing the 
amount of HPMC K 100M to retard the release of API I in Layer I. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Oral Anti hyperglycemic 856.00 
2 HPMC K100M Release retarding polymer 125.00 
3 HPMC 15 CPS Synergises the polymer effect 15.00 
3 Sodium Carboxy methyl cellulose Channelling agent 35.00  
4 Di-calcium phosphate Diluent 39.00 
5 Polyvinlypyrrolidone (Povidone) Binder 10.00 
6 Purified water Granulating solvent q.s. 
 Extra granular material   
7 Colloidal silicon dioxide Glidant 8.00 
8 Talc Glidant 4.00 
9 Magnesium Stearate Lubricant 8.00 
 Total  1100 
Table 13 Formula for F-5 Layer II 
• Amount of HPMC K100M was increased to improve sustained release of API I. 
 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 14 Formula for F-5 Layer II 
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TRIAL-6 (F6) 
AIM: To take a trial batch of Bi-layered tablets similar to Trial 5, but by addition of Polymer 
Extra-granularly to improve the sustained release of API I in Layer I. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Anti hyperglycaemic 856.00 
2 HPMC K100M  Release retarding polymer 125.00 
3 HPMC 15 CPS Synergises the polymer effect 15.00 
4 Sodium Carboxy methyl cellulose Channelling agent 35.00  
5 Di-calcium phosphate Diluent 14.00 
6 Polyvinlypyrrolidone (Povidone) Binder 10.00 
7 Purified water Granulating solvent q.s. 
 Extra granular material   
8 HPMC K 100M Polymer for retarding the release 25.00 
9 Colloidal silicon dioxide Glidant 8.00 
10 Talc Glidant 4.00 
11 Magnesium stearate Lubricant 8.00 
 Total  1100.00 
Table 15 Formula for F-6 Layer I 
 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15 Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.5000 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 16 Formula for F-6 Layer II 
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TRIAL-7 (F7) 
AIM: To take a trial batch of Bi-layered tablets as Trial 6, to check the reproducibility of 
Trail-6. 
LAYER - I 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
 Intra granular material   
1 API I Anti hyperglycaemic 856.00 
2 HPMC K100M  Release retarding polymer 125.00 
3 HPMC 15 CPS Synergises the polymer effect 15.00 
4 Sodium Carboxy methyl cellulose Channelling agent 35.00  
5 Di-calcium phosphate Diluent 14.00 
6 Polyvinlypyrrolidone (Povidone) Binder 10.00 
7 Purified water Granulating solvent q.s. 
 Extra granular material   
8 HPMC K 100M Polymer for retarding the release 25.00 
9 Colloidal silicon dioxide Glidant 8.00 
10 Talc Glidant 4.00 
11 Magnesium stearate Lubricant 8.00 
 Total  1100.00 
Table 17 Formula for F-7 Layer I 
LAYER-II 
S.No. INGREDIENTS USE Quantity per tablet (mg) 
1 API II Oral Anti- hyperglycemic drug 7.560 
2 Low Substituted Hydroxy Propyl Cellulose (LH-11) Dry Binder 12.000 
3 Lactose DCL 15  Diluent 162.940 
4 Croscarmellose sodium Disintegrant 12.000 
5 Indigo Caramine Lake Colouring agent 1.500 
6 Talc Glidant 2.000 
7 Magnesium Stearate Lubricant 2.000 
 Total  200 
Table 18 Formula for F-7 Layer II 
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Table 19 Compilation of Formulas of all Trials 
 
 
 
 
 
 
 
LAYER-I 
Ingredients F-1 F-2 F-3 F-4 F-5 F-6 F-7 
API I 856.00 856.00 856.00 856.00 856.00 856.00 856.00 
HPMC K 4M 170.00 - - - - - - 
HPMC K 15M - 170.00 - - - - - 
HPMC K 100M - - 100.00 100.00 125.00 125.00 125.00 
HPMC 15 CPS - - - 15.00 15.00 15.00 15.00 
Sodium CMC 35.00 35.00 35.00 35.00 35.00 35.00 35.00 
Dibasic Calcium 
Phosphate 19.50 11.00 80.00 65.00 39.00 14.00 14.00 
Povidone 7.50 8.00 9.00 9.00 10.00 10.00 10.00 
Purified water q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
HPMC K 100M - - - - - 25.00 25.00 
Colloidal Silicon 
Dioxide 8.00 8.00 8.00 8.00 8.00 8.00 8.00 
Talc 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
Magnesium Stearate 4.00 8.00 8.00 8.00 8.00 8.00 8.00 
Total 1100.00 1100.00 1100.00 1100.00 1100.00 1100 1100 
LAYER-II 
API II 7.560 7.560 7.560 7.560 7.560 7.560 7.560 
L.S.HPC (LH-11) 12.000 12.000 12.000 12.000 12.000 12.000 12.000 
Lactose DCL 15 62.940 162.940 162.940 162.940 162.940 162.940 162.940 
Croscarmellose Sodium 12.000 12.000 12.000 12.000 12.000 12.000 12.000 
Indigo Caramine Lake 1.500 1.500 1.500 1.500 1.500 1.500 1.500 
Talc 2.000 2.000 2.000 2.000 2.000 2.000 2.000 
Magnesium Stearate 2.000 2.000 2.000 2.000 2.000 2.000 2.000 
Total 100.00 200.00 200.00 200.00 200.00 200.00 200.00 
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TABLET BLEND ANALYSIS33: 
Blend of formulations is subjected for analysis to find out the Bulk density, Tapped 
density,    Compressibility index, Hausner’s ratio, Angle of repose. To determinate the 
occupancy of the blend in any equipment Blend analysis is important. The flow properties 
can be known from these parameters.   
 Angle of Repose 
 The angle of repose of each powder blend was determined by glass funnel method. 
Powders were weighed accurately and passed freely through the funnel so as to form a heap. 
The height of funnel was so adjusted that the tip of funnel just touched the apex of the heap. 
The diameter of the powder cone so formed was measured and the angle of repose was 
calculated by using the following equation, 
 
Where, 
              h = height of cone 
              r = radius of powder cone. 
 
Angle of repose (degrees) 
 
Type of flow 
 
<20 
 
Excellent 
 
20-30 
 
Good 
 
30-34 
 
Passable8 
 
>40 
 
Very poor 
 
 
 
      Table 20 Fate of flow property by change in angle of repose 
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 Bulk Density 
 Bulk density of the granules was determined by pouring gently 5 gm of sample 
through a glass funnel into a 10 ml graduated cylinder. The volume occupied by the sample 
was recorded. The bulk density was calculated by the following formula, 
Weight of samples in grams 
Volume occupied by the sample 
 Tapped Density 
About 5 gm of granule was poured gently through a glass funnel into a 10 ml 
graduated cylinder. The cylinder was tapped from height of 2 inches until a constant volume 
was obtained. Volume occupied by the sample after 50 taps were recorded and tapped density 
was calculated by the following formula, 
 
Weight of samples in grams 
Volume occupied by the sample 
 Carr’s Index 
One of the important measures that can be obtained from bulk and tapped density 
determinations is the percent compressibility or the Carr’s index, which is determined by the 
following equation, 
Compressibility Index Tapped density Bulk density
Tapped density
100= − ×
 
 Hausner’s Ratio 
Hausner’s ratio is related to inter-particle friction and as such used to predict powder 
flow properties. 
Hausner ratio Tapped density
Bulk density
=
 
 
Bulk Density = 
Tapped Density = 
 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore.  Page 60 
 
Table 21 FLOW PROPERTIES 
Compressibility index Flow character Hausner’s ratio 
5-10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.45 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
More than 40 Very very poor More than 1.60 
 
EVALUATION OF TABLETS34: 
Tablets are evaluated to check their mechanical strength that influences their Physico-
chemical characters like dissolution, absorption etc. Several parameters like: 
• Hardness. 
• Thickness. 
• Length and width. 
• Uniformity of weights. 
• Friability. 
• Assay  
HARDNESS TEST: 
Hardness of tablets is known from the pressure applied on it to form a crack along its 
axis. It is tested by using Dr. Schleuniger 8M tablet tester. The hardness of tablet is reported 
in Kg/cm2. Hardness of tablet influences the release of the drug from the tablet as a hard 
tablet takes a long time to disintegrate. Five tablets were tested during every trial.  
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Thickness and diameter: 
The thickness and diameter of tablets was carried out using Mitutoyo Vernier calliper. 
Five tablets were used for the above test from each batch results were expressed in milli-
meter. 
Weight variation test: 
Twenty tablets were selected at random, individually weighed in a single pan 
electronic balance and the average weight was calculated. The uniformity of weight was 
calculated. The uniformity of weight was determined according to I.P. specification. As per 
U.S.P not more than two of individual weight should deviate from average weight by more 
than 5% and none deviate more than twice that percentage. 
Friability test: 
  It was done in friability test apparatus where the tablets were subjected to the 
combined effect of abrasion and shock by utilizing a plastic chamber that revolve at 25 rpm 
dropping the tablets at a distance of six inches with each revolution. Pre-weighed samples of 
20 tablets were placed in the friability tester, which is then operated for 100 revolutions. The 
tablets were then dusted and reweighed. Conventional compressed tablets that loss than less 
than 1.0% of their weight are generally considered acceptable.                   
 
                        % Friability = {1-(Wt/W)} ×100 
                          Where % F = Friability in percentage 
                                         W = Initial weight of table 
                                         Wt = Weight of tablets after revolution. 
Assay34: 
The amount of API I & II in the dosage form units were determined using High 
Performance Liquid Chromatography.  
 
 
Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore.  Page 62 
 
Table 22 Chromatographic conditions for Assay 
Particulars API I API II 
Column C18 250 mm × 4.6 mm 10µ 
(Waters Bondapack  is 
suitable) 
C18 250 mm × 4.6 mm 5µ 
(Hypersil BDS C18 is suitable) 
Flow rate 1.0 ml/min. 1.0 ml/min. 
Detector UV/PDA detector UV/PDA detector 
Wavelength 218nm 270 nm 
Injection volume 20µl 20µl 
Column temperature 30°C 25°C
Run time 15 minutes 15 minutes 
Elution Isocratic Isocratic 
Buffer 1g of sodium heptanes 
sulphonte and 1g of Sodium 
chloride in 1800 ml of water 
and this is adjusted to pH 3.85 
with dilute Orthophosphoric 
acid. 
1.36 gms of Potassium 
dihydrogen phosphate in 
1000ml of water 
Mobile phase 900:100 ratio of buffer and 
aceonitrile 
500 : 500 ratio of buffer and 
acetonitrile  
Diluent Methanol  Mix water and acetonitrile in 
the ratio 350:650 respectively. 
Standard  50 mg of working standard in 
to 50 ml flask , add 35 ml of 
diluent, dilute up to 50 ml and 
mix well.5 ml of this is taken 
and this is added to 50 ml 
volumetric flask and this is 
diluted to 50 ml with diluents. 
The concentration would be 
100 ppm. 
41.5 mg of working standard 
is added to 50 ml volumetric 
flask and 20 ml of diluents is 
added and dilute it with 50 ml 
of diluents. 5 ml is taken and 
is diluted to 50 ml with dilunt. 
The concentration would be 
75 ppm. 
Sample 20 tablets were crushed and 
weighed equivalent to 1000mg 
of API I and added in to 500 
ml volumetric flask and this is 
added with 350 ml of diluents, 
shaken well and is diluted up 
to 500 ml with the diluent. 5 
ml is taken from this and this 
is diluted to 100 ml with the 
diluent. The concentration 
would be 100ppm. 
20 tablets were crushed and 
tablet powder equivalent to 7.5 
mg of API II was added to a 
100 ml volumetric flask and 
this mixed up with 70 ml of 
diluent. This is sonicated for 
about 20 minutes and this 
made up to 100 ml with the 
diluent.  The concentration 
would be 75 ppm. 
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Procedure for both the APIs: Equilibrate the column with the mobile phase until a 
baseline is obtained. Inject the sample and standard solutions. Record the chromatogram and 
measure the peak area response of both standard and sample preparations of the APIs. 
Calculation for percentage of API I and API II: 
 
 
 
 
 
 
¾ ATI and ATII  are the areas of the peaks obtained for the test solution of APIs in the 
chromatogram. 
¾ WSI and WSII are the weight of working standards of the APIs taken in Milligrams. 
¾ LCI and LCII  are the labelled amount of APIs in Milligrams per tablet. 
¾ PI and PII are the potencies of the APIs as on basis. 
 
 
 
 
                                                  ATI                   WSI                 5             100             AWII            PII        356.54 
                      % of API II =     -------- x ----------- x ----------- x ---------- x ---------- x -------- x    ----------x 100 
                                                  ASI                    100             50              WTII          LCII          100               392.95 
                                                  ATI                   WSI                 5             500           100            AWI        PI 
                      % of API I =     -------- x ----------- x ----------- x ---------- x ---------- x -------- x    ------x 100 
                                                  ASI                    50             50             WTI           5              LCI               100 
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In vitro DISSOLUTION STUDY34 
Dissolution studies become very important in characterization of the dosage forms 
particularly in case of sustained release dosage forms. They are also used to control the 
quality of dosage forms during the manufacturing process.  
In the In vitro dissolution study of the present study following parameters were 
employed to study the release characteristics of both the drugs from Immediate release (API 
II) and Sustained release layers (API I). 
Table 23 Dissolution conditions for API I and API II 
 The samples of study were analysed using High Performance Liquid chromatography. 
Chromatographic conditions used for both the APIs were given in the following tabular 
column. 
Particulars API I API II 
Column C18 250 mm × 4.6 mm 5µ 
(Waters Symmetry C18  is 
suitable) 
C18 250 mm × 4.6 mm 5µ 
(Hypersil BDS C18 is 
suitable)  
Flow rate 1.0 ml/min. 1.0 ml/min. 
Detector UV/PDA detector UV/PDA detector 
Wavelength 218 nm 270 nm 
Injection volume 20µl 20µl 
Column temperature 25°C 25°C 
Run time 10 minutes 15 minutes 
Elution Isocratic Isocratic 
Mobile phase 500 :500 v/v of buffer and 
aceonitrile 
500 : 500 v/v of buffer and 
acetonitrile  
Diluent Dissolution medium Dissolution medium 
Table 24 Chromatographic conditions for Dissolution study of API I & API II 
Dissolution parameters API I API II 
Medium pH 6.8 phosphate buffer 0.1N Hydrochloric acid 
Apparatus USP apparatus Type II USP Apparatus Type II 
Volume 900 ml 900 ml 
Agitation 100 rpm 100 rpm 
Measuring time 10 hours 45minutes 
Temperature 37°C±0.5°C 37°C ± 0.5°C 
Volume withdrawn 10 ml 10 ml 
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Standard preparation for API I: 
 Weigh accurately 55 mg of API I working standard and transfer to 100 ml volumetric 
flask and this diluted with 70 ml of diluent, sonicate to dissolve with intermittent shaking and 
make the volume up to 100 ml. Further dilute 10 ml of this solution in 100 ml volumetric 
flask with the diluent. The concentration of the API I working standard would be 55 ppm. 
Sample preparation for API I: 
 Set the dissolution apparatus as per above conditions. Place one tablet in each 
dissolution bowl. Rotate the paddle for 1st, 3rd and 10th hours with the RPM as mentioned 
above. Perform dissolution and withdraw sample aliquot at specified interval. Collect the 
filtrate after discarding first few ml of the filtrate. Dilute 3ml of filtrate to 50 ml with diluents 
at each time point and use the solution as sample preparation. The concentration would be 55 
ppm. 
System suitability: 
 The standard is injected in to the system and the system suitability parameters are 
checked. The %RSD of five replicate injections of API I should not be more than 2.0. 
Number of USP theoretical plates should not be less than 1500. In the chromatograms 
obtained for the API I standard, USP tailing factor should not be more than 2.0. 
Procedure: 
 Equilibrate the system with the mobile phase for sufficient time until stable baseline is 
observed. Inject dissolution medium as blank, standard preparation, sample preparation. 
Inject standard preparation as bracketing after six injections of sample preparation. 
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Calculation for percentage release of API I: 
                                 
        
Standard preparation for API II: 
 Weigh and transfer about 46.0mg of API II working standard (equivalent to 41.5 mg 
of pure form of API II) in to 100 ml volumetric flask. Add 70 ml of diluents and sonicate 
with intermittent shaking. Dilute this to 100 ml with diluent. Take 2 ml of this solution and 
dilute it to 100 ml with diluent. The concentration of API II would be 8.3 ppm. 
Sample preparation for API II: 
 Set the dissolution apparatus as per the above conditions. Place one tablet in each 
bowl of dissolution apparatus. Rotate the paddle for 45 minutes with the paddle spped 
mentioned above. Perform dissolution and withdraw the sample aliquot at specified time 
interval. Collect the filtrate after discarding few ml of filtrate.  The concentration of API II 
should be 8.3 ppm. 
System suitability: 
 The standard is injected in to the system and the system suitability parameters are 
checked. The %RSD of five replicate injections of API I should not be more than 2.0. 
Number of USP theoretical plates should not be less than 1500. In the chromatograms 
obtained for the API I standard, USP tailing factor should not be more than 2.0. 
 
                                                  ATI                   WSI                 10             900             50            100        PI 
% Drug release of API I =     -------- x ----------- x ----------- x ---------- x ---------- x -------- x    ----- 
                                                  ASI                    100             100              1           3              LCI               100 
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Procedure: 
 Equilibrate the system with the mobile phase for sufficient time until stable baseline is 
observed. Inject dissolution medium as blank, standard preparation, sample preparation. 
Inject standard preparation as bracketing after six injections of sample preparation. 
Calculation for percentage release of API I: 
                                 
        
• ATI and ATII are peak areas of API I and API II respectively obtained from their 
chromatograms. 
• ASI and ASII are the average of peak areas of API I and API II respectively obtained 
from their chromatograms. 
• WSI and WSII are the weights of working standards of API I and API II in mg. 
• LCI and LCII are labelled claim amount of API I and API II in mg per tablet. 
• PI and PII are percentage potency of APIs working standard potency. 
Specifications for Drug release: 
Drug Specification 
API I After 1st hour 25% to 50% 
After 3rd hour 45% to 75% 
After 10th hour  Not less than 80% 
API II Not less than 75% after 45 minutes. 
Table 25 Specification for Dissolution of API I & API II 
 
                                                  ATI I                  WSI I                2             900             100           PII        356.54 
% Drug release of API II =     -------- x ----------- x ----------- x ---------- x ---------- x -------- x   ----------- 
                                                  ASI I                    100             100           1          LCII            100               392.35 
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Data analysis36, 37: 
The data obtained from the dissolution study were subjected for analysis to know the 
release pattern of the drug from the dosage form. 
        To analyze the mechanism of release and release rate kinetics of the dosage form, the 
data obtained were fitted into Zero order, First order, Higuchi model, and Korsmeyer-Peppas 
model. Based on the r-value, the best-fit model was selected. 
 
Zero order kinetics: 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and release 
the drug slowly, assuming that the area does not change and No equilibrium conditions are 
obtained can be represented by the following equation, 
                          Q t = Q o + K o t 
 Where Q t = amount of drug dissolved in time t. 
  Q o = initial amount of the drug in the solution and 
  K o = zero order release constant. 
 
First order kinetics: 
 To study the first order release rate kinetics, the release rate data were fitted to the 
following equation, 
                            Log Qt = log Qo + K1t/2.303  
          Where Qt is the amount of drug released in time t, Qo is the initial amount of drug in 
the solution and K1 is the first order release constant. 
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Higuchi model: 
 To study the Higuchi release kinetics, the release rate data were fitted to the following 
equation, 
         ۴ ൌ ۹. ܜ
૚
૛      ܗܚ       ۴ ൌ ۹. √ܜ  
Where,    
‘F’ is the amount of drug release, ‘K’ is the release rate constant, and ‘t’ is the release time. 
When the data is plotted as a cumulative drug released versus square root of time, yields a 
straight line, indicating that the drug was released by diffusion mechanism. The slope is equal 
to ‘K’. 
Korsmeyer and Peppas release model: 
 The release rate data were fitted to the following equation, 
                                       
ۻܜ  
ۻಮ
 ൌ   ۹. ܜܖ 
Where, Mt /M∞ is the fraction of drug release, ‘K’ is the release constant, ‘t’ is the 
release time, and ‘n’ is the diffusion exponent for the drug release that is dependent on the 
shape of the matrix dosage form.  
When the data is plotted as Log fraction of drug released  versus Log time, yields a 
straight line with a slope equal to ‘n’ and the ‘K’ can be obtained from Y-intercept. 
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BLISTER PACKING OF DOSAGE FORM: 
 Packing of dosage forms is important for reasons like  
¾ Protection 
¾ Identification 
¾ Elegance 
¾ Ease of Shipping 
Blister packing is done for the selected formulation before being charged for the stability 
studies. 
Packaging of tablets: 
 Base foil and lidding foil were loaded in the machine .The tablets were loaded in the 
hopper. The base foil passes through the forming units with Teflon heads and cavities are 
formed. Tablets in the hopper coming down through inclined feeding channel and singling 
unit and are introduced into the cavities formed. The lidding foil is introduced and the 
sealing of the foils was done in the sealing station. The non-filled cavities are detected using 
non fill detecting system and are rejected by NFD rejection area. The cutting assembly and 
the trimming station cuts the blister into appropriate size. 
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STABILITY STUDIES38 
Introduction:    
 In any rational drug design or evaluation of dosage forms for drugs, the stability of 
the active component must be a major criterion in determining their acceptance or rejection. 
Stability of a drug can be defined as the time from the date of manufacture and the packaging 
of the formulation, until its chemical or biological activity is not less than a predetermined 
level of labeled potency and its physical characteristics have not changed appreciably or 
deleteriously. 
Objective of the Study:             
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of environmental 
factors such as temperature, humidity and light, enabling recommended storage conditions, 
re-test periods and shelf-lives. 
The International Conference on Harmonization (ICH) Guidelines titled “Stability 
Testing of New Drug substance and Products” (QIA) describes the stability test requirements 
for drug registration applications in the European Union, Japan and the United States of 
America. 
ICH specifies the length of study and storage conditions. 
Long-term Testing: 300C ± 20C / 65 % RH ± 5 % for 12 Months. 
Accelerated Testing:  400C ± 20C / 75 % RH ± 5 % for 6 Months. 
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Method: 
Stability studies were carried out at 300C / 65 % RH for 12 months and at 400C / 75 % 
RH for 6 months for the selected formulation. 
 The stability studies were done for the Formulation seven (F-7). This formulation was 
selected because of its reproducibility of the In vitro drug release of the drug from the 
sustained release layer of the Bi-layered tablets. The formulation was charged for stability at 
conditions 30°C/65% RH and 40°C/75%RH which are usually conditions for the Real time 
and Accelerated stability study.  
 The formulation was tested for parameters like appearance, assay, uniformity of 
weight, In vitro drug release. 
 
Table 26 Stability testing 
    
  
Formulation Stability condition Testing frequency 
Tested for 
Selected Formulation 
30°C/65% RH 
3rd month 
6thmonth 
9th month 
12th month 
 
Appearance, 
Assay, 
Uniformity of 
weights, 
  
In vitro drug release. 
 
40°C/75%RH 
1st month 
2ndmonth 
3rd month 
6thmonth 
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Evaluation of Active pharmaceutical ingredients:: 
 Physical parameters like Angle of repose, Bulk density, Tapped density, Carr’s index 
and Hausner’s index and Solubility of the APIs were determined and were given here in the 
table below. 
Parameter API I API II 
Solubility Freely soluble in water, 
practically insoluble in 
Acetone and methylene 
chloride. 
Soluble in N,N Dimethyl 
formamide and methanol. 
Angle of repose 32.00° 21.96° 
Bulk density 0.223g/cc 0.532 g/cc 
Tapped density 0.339g/cc 0.625g/cc 
Compressibility index 34.21% 14.894% 
Hausner’s ratio 1.520 1.174 
Loss on drying 0.25% 0.37% 
Assay 99.55% 99.37% 
 
Table 27 Results for Pre-formulation analysis of APIs 
The solubility, Loss on drying, Assay of the drugs are found to be within the specifications. 
From the Compressibility index, Angle of repose values of API I, it can be concluded that the 
API I has a poor flow and this can be improved by granulation. Flow properties of API II can 
be inferred as good. 
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COMPATIBILITY STUDIES 
 
 
 
 
Particulars Ratio Description 
Parameters 
Remarks 
25°C/60%RH 40°C/75%RH 
15  
days 
30  
days 15 days 30 days 
Complies 
API I 
Dry 
- 
White 
crystalline 
powder and 
mass 
No change No change No change No change 
Complies 
Aqueous 
Non-
aqueous 
API II 
Dry  
- 
White 
crystalline  
powder and 
mass 
No change No change No change No change 
Complies 
Aqueous 
Non-
aqueous 
API I    +  API II 2:1 White  powder No change No change 
No 
change No change 
Complies 
API I + HPMC K 4M 1:1 White powder No change No change 
No 
change No change 
Complies 
API I + HPMC K 15M 1:1 White powder No change No change 
No 
change No change 
Complies 
API I + HPMC K 
100M  1:1 
white 
powder 
mixture 
No change No change No change No change 
Complies 
API I + HPMC 15 CPS 1:0.25 White powder No change No change 
No 
change No change 
Complies 
API I + S-CMC 1:0.50 
 white 
powder 
mixture 
No change No change No change No change 
Complies 
API I + Lactose 
monohydrate 1:1 
White 
powder  No change No change 
No 
change No change 
Complies 
API I + Dibasic    
Calcium 
           phosphate 
1:0.50  white powder No change No change 
No 
change No change 
Complies 
API I + Povidone 1:0.25 
White 
powder 
mixture 
No change No change No change No change 
Complies 
API I + Aerosil 1:0.25 White powder No change No change 
No 
change No change 
Complies 
API I + Talc 1:0.25 White powder No change No change 
No 
change No change 
Complies 
API I + Magnesium 
stearate 1:0.25 
White 
powder No change No change 
No 
change No change 
Complies 
API II + L.S. HPC 
(LH- 11) 1:1 
Off white 
powder No change No change 
No 
change No change 
Complies 
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COMPATIBILITY STUDIES 
 
Table 28 Results of Compatibility studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Particulars Ratio Description 
Parameters Remarks 
25°C/60%RH 40°C/75%RH  
15  
days 
30  
days 
15  
days 
30 
 days Complies 
API II + CCS 1:1 
Off white 
powder 
mixture
No change No change No change No change Complies 
API II + Indigo 
caramine lake 1:0.50 
Sky blue 
coloured 
powder
No change No change No change No change Complies 
API II + Talc 1:0.5 
White 
coloured 
powder 
No change No change No change No change Complies 
API II + 
Magnesium 
Stearate 
1:0.5 
White 
coloured 
powder 
No change No change No change No change Complies 
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IR studies: 
 The samples that were charged in 45°C/75% RH stability chambers were analysed by 
IR spectroscopy after 30 days. The graphs of the samples were given below. 
 
 
 
 
Figure 2 showing IR-graph of API I + HPMC 15 CPS. 
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Figure 5 showing IR graph of API I + HPMC K 100M 
 
 
Figure 6 showing IR graph of API I + Sodium CMC 
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Figure 7 Showing IR graph of API II + L.S. HPC (LH-11) 
               
 
Figure 8 showing IR graph of API II + Lactose DCL 15 
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   Figure 09 showing IR graph of API II + Croscaramellose Sodium 
 
 
 
Discussion: 
From the IR studies and Physical observation it can be concluded that there 
will be no possible chemical interaction between the excipients and the drugs. So 
these excipients were used for the formulation of the Bi-layered tablets. 
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TABLET BLEND ANALYSIS: 
The results of the blend analysis performed for all the formulations are given here in the 
Table I and table II below for both the layers. 
FOR LAYER I 
Formulation Angle of repose 
Bulk 
density(g/cc)
Tapped 
density(g/cc) Carr’s index 
Hausner’s 
ratio 
F-1 17.7 0.4969 0.5689 12.56 1.144 
F-2 18.1 0.5290 0.5946 11.03 1.124 
F-3 18.9 0.5156 0.5803 11.14 1.125 
F-4 18.4 0.5109 0.5813 12.11 1.137 
F-5 18.2 0.4555 0.5316 14.31 1.167 
F-6 19.1 0.5076 0.5697 10.90 1.122 
F-7 18.5 0.4925 0.5480 10.12 1.112 
Table 29 Results of Tablet blend analysis of Layer I  
FOR LAYER II 
Parameter Angle of repose 
Bulk 
density(g/cc)
Tapped 
density(g/cc) 
Carr’s 
index 
Hausner’s 
ratio 
F-1 16.9 0.5219 0.5882 11.27 1.12 
F-2 16.7 0.5555 0.6125 9.30 1.10 
F-3 17.5 0.5434 0.5995 9.35 1.10 
F-4 16.3 0.5747 0.6354 9.55 1.10 
F-5 16.9 0.5813 0.6403 9.21 1.10 
F-6 16.5 0.5681 0.6260 9.24 1.10 
F-7 17.1 0.5370 0.5930 9.44 1.10 
Table 30 Results of Tablet blend analysis of Layer I  
 
The powder characteristics of all the formulations (for Layer I & Layer II) were found to be 
good and have shown no problems during the process. The reason for this can be: 
• Angle of repose was less than 20 that implies excellent flow properties of 
formulations. 
• Carr’s index and Hausner’s ratio were also found to be in optimum range by which 
the blends can be concluded to be possessing good flow properties. 
The use of the wet granulation technique for the Layer-I in all the formulations and suitable 
diluents, glidants and lubricants in optimum percentages for Layer-II resulted in tablet blends 
with optimum powder characteristics which are always important during processing of 
tablets. 
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TABLET EVALUATION: 
The prepared tablets were subjected to preliminary characterization such as hardness, 
thickness, % weight variation, friability and drug content. The evaluated parameters were 
within acceptable range for all the   formulations. The values are indicated in below Table. 
                  Table 31 Specifications for preliminary characterization of formulations 
Parameters Range 
Hardness (kg/cm2) 9-12 
Thickness (mm) 7.00mm-7.30 mm 
Weight variation (%) ±5% 
% Friability Not more than 1.0% 
Assay (%) 
API I 95.0-105.0 
API II 90.0-110.0 
 
Results of preliminary characterization of tablets for all formulations were given below: 
Table 32 Results of Tablet evaluation 
Discussion: 
 From the results it can be concluded that the results of all the formulations were found to be 
within specifications. The tablets are subjected for In vitro dissolution study. 
Parameters F-1 F-2 F-3 F-3 F-5 F-6 F-7 
Hardness 
(Kg/cm2) 
(n = 10) 
9.16 9.54 9.59 10.50 10.08 10.50 10.30 
Thickness 
(mm) 
(n = 10) 
7.08 7.01 7.04 7.10 7.02 7.05 7.12 
Friability 
(%) 0.337 0.367 0.305 0.398 0.420 0.377 0.342 
 Weight 
variation 
-1.9 to 
+2.7 
-2.9 to 
+3.4 
-2.9 to 
3.9 
-1.8 to 
2.9 
-4.1 to 
3.2 
-1.9 to 
2.2 
-2.4 to 
2.8 
% 
Drug 
content 
API I 98.81 99.42 97.34 101.42 99.73 98.36 98.75 
API 
II 
 
98.19 
 
99.08 98.54 98.84 98.12 99.63 99.81 
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In-VITRO RELEASE STUDY 
The Dissolution profiles of the formulations of Bi-layered tablets were obtained by the 
procedure reported earlier and the results were shown in following tables. 
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Dissolution profile of formulation 1 (F-1): 
 
Table 33 Dissolution Profile of F-1 
Discussion: The use of low viscosity polymer i.e. HPMC K 4M could not retard the release 
of drug as desired during the 1st and 3rd hours. So it was decided to use HPMC K 15M for the 
next trial. The drug from the immediate release layer released as desired. 
 
 
 
 
 
 
 
 
 
Layer I 
 
 
Medium Time 
(Hours) 
Cumulative Percentage release Average
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 64.3 65.4 64.9 63.0 69.1 65.0 65.2 
3rd 
 83.4 84.1 84.0 83.2 82.2 81.04 82.9 
10th 99.1 99.0 98.8 99.5 97.1 98.2 98.6 
Layer II 
0.1N HCl After  45 minutes 97.3 98.1 97.5 97.0 96.5 98.0 97.4 
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Dissolution profile of formulation-2 (F-2) 
 
Table 34 Dissolution Profile of F-2 
 
Discussion: Although the percentage release of the drug at 1st and 3rd hour did retard after 
using HPMC K 15M instead of HPMC K 4M, the rate profile is not as desired. In the next 
trial it was decided to use HPMC K 100M as a release retardant polymer.  
 
 
 
 
 
 
 
 
  
Layer I 
 
 
Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 60.4 62.2 61.3 60.9 62.4 60.7 61.3 
3rd 
 78.8 77.6 78.3 79.0 78.2 79.5 78.5 
10th 99.1 98.9 98.4 99.2 100.10 99.4 99.2 
Layer II 
0.1N 
HCl 
After 
45minutes 90.1 95.4. 93.3 94.1 95.1 96.1 94.0 
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Dissolution profile of formulation-3 (F-3) 
Table 35 Dissolution Profile of F-3 
Discussion: The release rate of the drug in the SR layer did not come within specifications 
here in the 3rd formulation also after using high viscosity HPMC. But there was a reduction in 
the rate of release of the drug when compared to formulation-2. In the next trial it was 
decided to incorporate HPMC 15 CPS as an adjuvant to HPMC K 100M. 
Figure 13 Showing Dissolution profile of API I from Formulations 1, 2 & 3 
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Layer I 
 
 
Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 56.7 58.5 57.2 56.9 57.7 58.0 57.4 
3rd 
 76.3 75.5 76.0 77.1 75.9 76.3 76.1 
10th 99.8 98.7 100.1 101.4 99.5 100.7 100.0 
Layer II 
0.1N HCl After 45minutes 94.1 93.5 90.9 94.8 92.1 92.8 93.03 
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Dissolution profile of formulation-4 (F-4) 
 
Table 36 Dissolution profileof F-4 
Discussion: The use of HPMC 15 CPS inhibited the release of the drug as expected, which is 
shown by the difference between release rates of the previous formulation and this 
formulation. But the release rate did not come under specifications. So a trial was decided 
with an increase of the HPMC K 100M than formulation-4. 
 
 
 
 
 
 
 
 
 
 
Layer 
 
 
Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 50.1 53.2 52.9 54.1 51.1 53.6 52.5 
3rd 
 74.9 75.0 75.9 74.7 76.1 75.4 75.3 
10th 98.7 99.8 98.2 99.5 98.6 99.1 99.9 
Layer II 
0.1N HCl After 45minutes 94.2 93.3 92.8 93.9 95.1 94.8 94.01 
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Dissolution profile of Formulation-5 (F-5) 
 
Table 37 Dissolution Profile of F-5 
 
Discussion: The release rate of the drug could be reduced with an increase in the 
concentration of the polymer and is almost within the specification. To improve the release 
profile better than that of this formulation, a trial was taken by incorporating HPMC K 100M 
extra-granularly in formulation-6 (F-6) 
Figure 14 Dissolution Profile of API I from Formulation 4 & 5 
              
 
0
20
40
60
80
100
120
0 2 4 6 8 10 12
%
CD
R
Time (Hours)
Formulations F-4&F-5
F‐4
F‐5
Layer I 
 
 
Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 47.8 49.4 51.2 48.9 50.4 51.2 49.8 
3rd 
 71.5 71.9 73.4 72.9 71.3 73.9 72.5 
10th 98.6 99.1 99.7 99.4 97.4 97.9 98.7 
Layer II 
0.1N HCl After 45minutes 93.7 94.1 94.9 92.9 96.1 95.4 94.5 
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Dissolution profile of formulation-6 (F-6) 
 
 
Table 38 Dissolution profile of F-6 
 
Discussion: Extra-granularly added HPMC K 100M has helped in obtaining the desired 
release profile of the drug in SR layer at 1st and 3rd hours. A reproducibility trial was planned 
with same formula as F-6, to check the consistency of the formulation. 
         
                     
 
 
 
 
 
 
 
 
 
Layer I 
 
 
Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 36.4 36.5 37.8 37.2 36.9 37.5 37.0 
3rd 
 68.0 70.1 71.9 68.7 70.5 69.5 69.7 
10th 100.6 100.0 100.5 100.4 101.9 101.2 101.7 
Layer II 
0.1N HCl After 45minutes 93.3 93.9 94.1 93.9 94.4 94.7 94.0 
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Dissolution profile of formulation-7 
 
 
Table 39 Dissolution profile of F-7 
 
Discussion: The release profile of the F-7 was found to be similar to that of the F-6 that is 
within specification.  
Figure 15 Dissolution Profile of API I F-6 & 7. 
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Medium Time (Hours) 
Cumulative Percentage release Average 
pH 6.8 
buffer 
Unit-1 Unit-2 Unit-3 Unit-4 Unit-5 Unit-6 
1st 39.9 38.7 39.2 37.7 37.5 39.2 38.7 
3rd 
 71.3 72.0 71.9 70.8 70.6 71.9 71.4 
10th 98.9 98.3 101.5 99.7 98.6 99.9 99.5 
Layer II 
0.1N HCl After 45minutes 94.2 93.9 95.2 93.9 96.8 95.0 94.83 
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Figure 16 Shows Dissolution Profile of API II in all Formulations 
                      
Discussion: There was no change in formula of Layer-II as there was good and consistent 
release of the API II in all the formulations. The immediate disintegration of the layer within 
45 minutes can be posed as the reason for the complete release of the API II withi45 minutes.   
 
 
Time F-1 F-2 F-3 F-4 F-5 F-6 F-7 
After 45 
minutes 97.4 94.0 93.03 94.01 94.5 94.0 94.83 
Table 40 Dissolution profiles of all the formulations 
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F‐1 F‐2 F‐3 F‐4 F‐5 F‐6 F‐7
Percentage release of API II
from all Formulations
Time F-1 F-2 F-3 F-4 F-5 F-6 F-7 
1st hour 65.2 61.3 57.4 52.5 49.8 37.0 38.7 
3rdhour 82.9 78.5 76.1 75.3 72.5 69.7 71.4 
10th hour 98.6 99.2 100.0 99.9 98.7 101.7 99.5 
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Kinetic study: 
 Formulation-7 was found to be giving the desired Invitro dissolution rate, so this 
formulation was selected for determining the nature of release of drug from dosage form. 
Time 
(in hours) 
Square root 
of time Log Time % CDR 
Log(100% -
CDR) 
Log 
%CDR 
0 0 - 0 2 0 
1 1 0 38.7 1.78 1.58 
3 1.73 0.47 71.41 1.45 1.85 
10 3.16 1 99.45 -0.259 1.99 
Table 41 Graphs for the different Kinetic models were plotted as per above values.  
 
Table 42 Regression coefficients and Slopes from all the Kinetic model graphs 
 
 
Discussion:  The curve fitting results of the release rate profile of the designed formulations 
gave an idea on the mechanism of drug release. 
 Based on the data analysis the drug release was found to follow First order release 
kinetics, the drug release mechanism was best explained by first order, as the plots showed 
the highest linearity. This model indicates a coupling of the diffusion and erosion mechanism 
(Anomalous diffusion) and indicates that the drug release was controlled by more than one 
process. 
  
Formulation Zero-order kinetics 
First-order 
kinetics 
Higuchi’s 
kinetics 
Korsmeyer-
Peppas 
F-7 
Slope R2 Slope R2 Slope R2 Slope R2 
8.425 0.786 0.227 0.996 31.65 0.964 -0.406 0.954 
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STABILITY STUDY DATA 
The samples from the stability chambers that were packed in PVC Blister packing 
were subjected to following analysis. 
 
Table 43 Stability Data for the samples stored at condition 30º C/65 %RH 
 
Parameter Specifications Initial 3 months 
Appearance 
White/Blue oblong 
shaped Bi-layered tablets 
No change 
 
No change 
 
Average Weight (n= 20) 1300 mg ± 5 % 1311.2 mg 1312.5 mg 
Weight variation ± 5% -2.0%  to +1.9% -3.0% to 4.1% 
Assay  API I 
90.0% to 110.0% of 
stated amount of API I 
98.35% of API I 98.70% of API I 
Assay API II 
90.0%to 110.0% of stated 
amount of  
API II 
99.33% of API II 99.6% of API II 
In vitro drug 
release study 
API I 
1st Hour 25% to 50 % 36.3% to 40.9% 35.9% to 40.6% 
3rd Hour 45% to 75 % 66.8 to 72.6% 68.0 to 69.3% 
10th hour NLT 80% 90.0% to 96.7% 98.3% to 100.5% 
API II 
Within 15minutes 
NLT 75% 
93.0% 94.6% 
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Table 44 Stability data for the samples stored at condition 40°C/75%RH  
  
Discussion: From the stability data provided above, it can be concluded that the Formulation was 
stable at both the conditions. This is because all parameters checked were within specifications.  
  
Parameter Specifications First month Second month Third month 
Appearance 
White/Blue oblong 
shaped Bi-layered 
tablets 
No change 
 
No change 
 
No change 
Average Weight  
(n= 20) 
1300 mg ± 5 % 1296.9mg 1300.4 1306.5 mg 
Weight variation ± 5% -2.1% to +3.1% -3.5% to +3.2% -2.2% to +3.8% 
Assay  API I 
90.0% to 110.0% of 
stated amount of API I 
98.5% of API I 99.17% of API I 98.8% of API I 
Assay API II 
90.0%to 110.0% of 
stated amount of API II 
99.33% of API II 99.6% of API II 
 
99.06% of API II 
In vitro 
drug 
release 
study 
API I 
1st 
Hour 
25% to 50 % 33.8% to 35.9% 34.5% to 39.5% 35.2% to 37.0% 
3rd 
Hour 
45% to 75 % 65.5% to 67.6% 64.8% to 71.6% 67.1% to 69.9% 
10th 
hour 
NLT 80% 97.9% to 99.6% 97.9% to 99.3% 99.0% to 100.8% 
API II 
Within 15minutes 
NLT 75% 
95.0% 94.2% 97.6% 
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9. SUMMARY 
Tablets are oral solid dosage forms which are formed by compressing fixed volumes 
of powder particles comprising of the active pharmaceutical ingredients and other excipients. 
Tablets are most used dosage forms than other oral dosage forms. There are of different types 
based on the nature of administration, manufacturing. Bi-layered tablets are one of a kind of 
tablets which are manufactured when there is need of separation of two or for releasing a 
drug in different manner i.e. as sustained release and immediate release. These are generally 
manufactured in specially designed tablet presses. Bi-layered tablets can have two drugs in 
which one can release immediately and the other will be sustained for longer durations.  
 Diabetes is chronic metabolic disorder in which there would be increased glucose 
levels in the body. It is of two types’ Insulin-Dependent diabetes and Non-Insulin Dependent 
diabetes. Diabetes is generally treated by using Insulin and Oral-Hypoglycemic drugs. 
Biguanides, Sulfonylureas, Thiazoliddinediones, Meglitinides, Alpha-Glucosidase inhibitors 
are the five classes of the Oral-Hypoglycemic drugs. These act by decreasing Insulin 
resistance of cells. Biguanides and Thiazolidinediones are used in combination when therapy 
with single Oral-Hypoglyemic agent is not satisfying. 
 In the present study a Biguanide and a Thiazolidinedione are selected for the 
designing Bi-layered tablets with the Biguanide in SR layer and Thiazolidinedione in IR 
layer. Pre-formulation studies were done with APIs. Compatibility was analysed before 
choosing the excipients for the study with physical observation and IR studies. The samples 
were charged in stability chambers of conditions 25°C/60%RH and 40°C/75%RH for 30 
days. All the pre-formulation studies and compatibility studies are found to be satisfactory 
and so formulation trails were started with the selected excipeints. 
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 Blend for SR layer was prepared by wet granulation and IR layer blend is prepared 
by dry mixing. HPMC K 4M, HPMC K 15M and HPMC K 100M were used as release 
retarding polymers for Layer I for trials in optimizing the formula. Other excipients include 
Sodium CMC, HPMC 15 CPS and Di-basic Calcium Phosphate, Colloidal Silicon Dioxide, 
Talc and Magnesium stearate.  
Seven trials were done to optimize the release of API I in SR layer to be within 
specifications. F- 6 is the optimized formula with 12% of HPMC K 100M intra-granularly 
and 2.5% of same polymer extra-granularly. A reproducibility trail as F-7 was done which 
also gave results as F-6. For the IR layer, formula is kept constant as there is sufficient 
release of the drug was observed from the second trial. Direct mixing is done with 
Croscaramellose as super-disintegrant. Other excipients include Low substituted HPC (LH-
11) as binder, Lactose DCL 15 as diluent, Talc and Magnesium stearate.  
Post-Compression analysis of all formulations like Hardness, Weight variation, 
Friability and Assay were optimum for all the formulations. In-vitro dissolution studies 
revealed that for the formulation F-6 the sustained release layer released the drug as per the 
specifications. The same was reproduced in the formulation F-7. Stability studies were 
initiated for F-7 at conditions 30°C/45%RH and 40°C/75%RH for a period 12 months and 6 
months respectively. The results obtained after 3 months for samples at both the conditions 
were found to be satisfactory and so the product is stable. 
Kinetic Model fitting was done by plotting graphs for Zero-Order kinetics, First-Order 
kinetics, Higuchi’s Kinetic model and Korsemeyer-Peppas kinetic model. The formulation 
selected was F-7 which has shown the release rate of the drug is by First order kinetics. The 
release mechanism is both by erosion and diffusion mechanism. 
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10. CONCLUSION 
 The aim of the study is to design and develop immediate release and sustained release 
bi-layered matrix tablets of Oral-Hypoglycemic drugs. A Biguanide and a Thiazolidinedione 
were selected for the sake of study. HPMC, water swell able polymer and Croscaramellose 
sodium a superdisintegrant were selected for the sustained release of API I and Immediate 
release of API II respectively. 
 The formulation was optimized to obtain the release of API I for a sustained period 
(within specification). In the initial trials HPMC low viscosity polymer is selected to check 
the feasibility of the polymer to sustain the release of API I. In later trials HPMC high 
viscosity grades were employed, which gave the desired release of the API I.  
With low viscosity polymers like HPMC K 4M did not sustain the release of API I to 
the desired level. Use of HPMC K 15M did reduce the release of drug in the layer I compared 
to that of formulation with HPMC K 4M. But that was not an optimum profile. So a still high 
viscous polymer HPMC K 100M was used in the formulations F-3 to F-7. To enhance the 
activity of the Polymer, HPMC 15 CPS is used that effectively reduced the release rate. The 
incorporation of the Polymer intra-granularly and extra-granularly at concentration 12% and 
2.5% respectively gave an optimum release profile within specifications. From this it can be 
conclude on increasing the polymer concentration, the release rate of the drug sustains. We 
can also conclude that the use of HPMC 15 CPS worked as an adjuvant to the sustained effect 
shown by HPMC K 100M.  
The release of API II was constant all through the formulation. This concludes that 
the superdisintegrant played good role in disintegrating the Layer II. 
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From graphs plotted for various Kinetic models, it can be concluded that the F-7 is 
following First-order kinetic as the plots of that model had shown higher regression values 
(R2=0.9960). The release mechanism can be concluded both by diffusion and erosion 
mechanisms.  
From the stability studies completed for 3 months, it can be concluded that the 
formulation is stable one, as all the parameters like Appearance, assay of the drugs and 
Consistency in dissolution studies were found to be intact, even after simulating extreme 
conditions during their storage. Further, the stability studies would be continued                     
in Micro Labs Ltd. 
From this can be concluded that Bi-layered matrix tablets comprising Oral-
Hypoglycemic drugs in immediate release layer and sustained release layer are a good means 
in promising a combination therapy, while achieving patient compliance for Diabetic 
Mellitus.  
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